Cyclacel Pharmaceuticals (CYCC) Receives Media Impact Score of 0.28

Media headlines about Cyclacel Pharmaceuticals (NASDAQ:CYCC) have been trending positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cyclacel Pharmaceuticals earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.4386189722434 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

Shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) traded down 0.904% during midday trading on Tuesday, reaching $1.645. The company’s stock had a trading volume of 286,569 shares. The company has a 50-day moving average price of $1.73 and a 200-day moving average price of $3.82. Cyclacel Pharmaceuticals has a 12 month low of $1.56 and a 12 month high of $10.90.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.50) earnings per share for the quarter. Cyclacel Pharmaceuticals had a negative return on equity of 68.88% and a negative net margin of 1,128.13%. On average, equities research analysts predict that Cyclacel Pharmaceuticals will post ($2.25) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was published by BBNS and is the property of of BBNS. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://baseballnewssource.com/markets/favorable-news-coverage-somewhat-unlikely-to-impact-cyclacel-pharmaceuticals-cycc-stock-price/1529394.html.

In related news, major shareholder Eastern Capital Ltd purchased 850,000 shares of the stock in a transaction on Wednesday, July 19th. The shares were purchased at an average price of $2.00 per share, with a total value of $1,700,000.00. Following the transaction, the insider now directly owns 2,167,261 shares of the company’s stock, valued at $4,334,522. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 4.00% of the stock is owned by insiders.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.

Insider Buying and Selling by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Receive News & Ratings for Cyclacel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game


Leave a Reply

 
© 2006-2017 BBNS.